A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 1, 2008, Pages 89-94

  Viel, Erika ^a   Demarchi, Martin Frederico ^a   Chaigneau, Loic ^a   Nguyen, Thierry ^a   Legat, Christine ^a,b   Stein, Ulrich ^a   Thiery Vuillemin, Antoine ^a   Limat, Samuel ^a,b   Pivot, Xavier ^a,c   Borg, Christophe ^a,c  

^a Department of Medical Oncology ^*  (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Colorectal cancer; FOLFIRI3; Irinotecan

Indexed keywords

ACETORPHAN; ANTIDIARRHEAL AGENT; ATROPINE; DIOSMECTITE; FLUOROURACIL; FOLINATE CALCIUM; IRINOTECAN; LOPERAMIDE; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FOLINIC ACID; IFL PROTOCOL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OUTPATIENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; COMPARATIVE STUDY; DRUG RESISTANCE; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 42449116642     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318134ee9c     Document Type: Article

References (28)

1. Colorectal cancer. In: Stewart BW, Kleihues P, eds. World Cancer Report. Lyon: IARC Press; 2003:198-202.
2. Kelly A, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23:4553-4560.
3. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-657.
4. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212-2221.
5. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
6. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucoverin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
7. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet. 2000;355:1041-1047.
8. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucoverin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.
9. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352: 1407-1412.
10. De Gramont A, Figer A, Seymour M, et al. Leucoverin end fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
11. Maiello E, Gebbia V, Giuliani F, et al. FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol. 2005;16:56-60.
12. Andre' T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition bimonthly, high-dose leucoverin and bolus and continuousinfusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer. 1999;35:1343-1347.
13. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol. 2006;24:394-400.
14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucoverin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
16. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808-815.
17. Jaxel C, Kohn KW, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989;49:1465-1469.
18. Goldberg RM, Sargent D, Morton RF, et al. A randomised controlled trial of fluorouracil plus leucoverin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
19. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
20. Guichard S, Cussac D, Hennebelle I, et al. Sequence dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer. 1997;73:729-734.
21. Guichard S, Hennebelle I, Bugat R, et al. Cellular interaction of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in human colorectal carcinoma cell line. Biochem Pharmacol. 1998;55:667-676.
22. Mans DRA, Grivicich I, Peters GJ, et al. Sequence dependent growth inhibition and DNA damage formation by the irinotecan-5fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer. 1999; 13:1851-1861.
23. Mabro M, Louvet C, Andre T, et al. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. Am J Clin Oncol. 2003;26:254-258.
24. Mabro M, Artru P, Andre T, et al. A phase II study of FOLFIRI 3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer. 2006;94:1287-1292.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidlines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
26. Kemeny N, Garay CA. Randomised multicenter phase II trial of bolus plus infusional fluorouracil/leucoverin compared with fluorouracil/leucoverin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol. 2004;22:4753-4761.
27. Chong G, Dickson JLB, Cunningham D, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005;93:510-514.
28. Recchia F, Saggio G, Nuzzo A, et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer. 2004;91:1442-1446.